The effect of trihexyphenidyl, an anticholinergic agent, on regional cerebral blood flow and oxygen metabolism in patients with Parkinson's disease

Journal of the Neurological Sciences

Volumn 167, Issue 1, 1999, Pages 56-61

  Takahashi, Satoshi ^a   Tohgi, Hideo ^a   Yonezawa, Hisashi ^a   Obara, Satoko ^a   Yamazaki, Etsuko ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Anticholinergics; Cerebral blood flow; Oxygen metabolism; Parkinson's disease; Positron emission tomography (PET); Trihexyphenidyl

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; TRIHEXYPHENIDYL;

ADULT; ARTICLE; BRAIN BLOOD FLOW; BRAIN OXYGEN CONSUMPTION; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; HUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

CEREBROVASCULAR CIRCULATION; CHOLINERGIC ANTAGONISTS; FEMALE; HUMANS; MALE; MIDDLE AGED; OXYGEN CONSUMPTION; PARKINSON DISEASE; TOMOGRAPHY, EMISSION-COMPUTED; TRIHEXYPHENIDYL;

EID: 0032779759     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(99)00142-2     Document Type: Article

References (25)

1. de Smet Y, Ruberg M, Serdaru M, Dubois B, Lhermitte F, Agid Y. Confusion, dementia and anticholinergics in Parkinson's disease. J Neurol Neurosurg Psychiatry 1982;45:1161-4.
2. Schelosky L, Benke T, Poewe WH. Effects of treatment with trihexyphenidyl on cognitive function in early Parkinson's disease. J Neural Transm Suppl 1991;33:125-32.
3. Sadeh M, Braham J, Modan M. Effects of anticholinergic drugs on memory in Parkinson's disease. Arch Neurol 1982;39:666-7.
4. Kurlan R, Como P. Drug-induced alzheimerism. Neurology 1988;45:356-7.
5. Mizuno T, Nishiyama K, Hitoshi S, Takeda K, Sakuta M. The effect of anticholinergic drugs on I-IMP SPECT in Parkinson's disease. Clin Neurol (Tokyo) 1992;32:375-80.
6. Nishiyama K, Mizuno T, Sakuta M, Kurisaki H. Chronic dementia in Parkinson's disease treated by anticholinergic agents. Neuropsychological and neuroradiological examination. Adv Neurol 1993;60:479-83.
7. Nishiyama K, Momose T, Sugishita M, Sakuta M. Positron emission tomography of reversible intellectual impairment induced by longterm anticholinergic therapy. J Neurol Sci 1995;132:89-92.
8. The American Psychiatric Association. Diagnostic and statistical manual of mental disorders. DSM-III-R. 3rd ed. Washington, DC: American Psychiatric Association, 1987.
9. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-96.
10. Takahashi S, Tohgi H, Yonezawa H, Obara T, Nagane Y. Cerebral blood flow and oxygen metabolism before and after a stroke-like episode in patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS). J Neurol Sci 1998;158:58-64.
11. Phelps ME, Huang SC, Hoffman EJ, Kuhl DE. Validation of tomographic measurement of cerebral blood volume with C-11-labeled carboxyhemoglobin. J Nucl Med 1979;20:328-34.
12. Lammertsma AA, Jones T. Correction of the presence of intravascular oxygen-15 in the steady-state technique for measuring regional extraction ratio in the brain: 1. Description of the method. J Cereb Blood Flow Metab 1983;3:416-24.
13. Lenzi GL, Jones T, Reid JL, Moss S. Regional impairment of cerebral oxidative metabolism in Parkinson's disease. J Neurol Neurosurg Psychiatry 1979;42:59-62.
14. Wolfson LI, Leenders KL, Brown LL, Jones T. Alterations of regional cerebral blood flow and oxygen metabolism in Parkinson's disease. Neurology 1985;35:1399-405.
15. Wooten GF, Collins RC. Effects of dopaminergic stimulation on functional brain metabolism in rats with unilateral substantia nigra lesions. Brain Res 1983;263:267-75.
16. Koller WC. Disturbance of recent memory function in parkinsonian patients on anticholinergic therapy. Cortex 1984;20:307-11.
17. Dörje F, Wess J, Lambrecht G, Tacke R, Mutschler E, Brann MR. Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J Pharmacol Exp Ther 1991;256:727-33.
18. Lin SC, Olson KC, Okazaki H, Richelson E. Studies on muscarinic binding sites in human brain identified with [3H] pirenzepine. J Neurochem 1986;46:274-9.
19. Levey AI. Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci 1993;52:441-8.
20. Lambrecht G, Feifel R, Moser U, Aasen AJ, Waelbroeck M, Christophe J, Mutschler E. Stereoselectivity of the enantiomers of trihexyphenidyl and its methiodide at muscarinic receptor subtypes. Eur J Pharmacol 1988;155:167-70.
21. Boulanger CM, Morrison KJ, Vanhoutte PM. Mediation by M3-muscarinic receptors of both endothelium-dependent contraction and relaxation to acetylcholine in the aorta of the spontaneously hypertensive rat. Br J Pharmacol 1994;112:519-24.
22. Nakano I, Hirano A. Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease. Ann Neurol 1984;15:415-8.
23. Ruberg M, Ploska A, Javoy-Agid F, Agid Y. Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia. Brain Res 1982;232:129-39.
24. Lange KW, Wells FR, Jenner P, Marsden CD. Altered muscarinic and nicotinic receptor densities in cortical and subcortical brain regions in Parkinson's disease. J Neurochem 1993;60:197-203.
25. Suhara T, Inoue O, Kobayashi K, Suzuki K, Tateno Y. Age-related changes in human muscarinic acetylcholine receptors measured by positron emission tomography. Neurosci Lett 1993;149:225-8.